Cancer - Prostate(구연) Oral Session 1 / Cancer - Prostate (Ⅰ) (O-006) Grand Ballroom(2F) 11월28일(수) 13:00-14:00 일차 치료로 남성호르몬 박탈요법으로 치료받는 전립선암 환자에서 병합호르몬 차단요법과 LHRH 유사체 단독요법 간에 환자 삶의 질 비교 을지대학교 의과대학 비뇨기과학교실.¹ 경희대학교 의과대학 비뇨기과학교실.² 고려대학교 의과대학 비뇨기과학교실.³ 성균관대학교 의과대학 삼성서울병원 가정의학과. ⁴ 신현빈¹, 박현식¹, 우승효¹, 전승현², 강석호³, 신동욱⁴, 박진성¹ Purpose: Both combined androgen blockade (CAB) and LHRH agonist alone is commonly used for androgen deprivation therapy (ADT), while there are few studies investigating patient quality of life (QOL) following ADT. In this randomized clinical trial, we aimed to compare patients’ QOL according to the ADT method in prostate cancer (PC) patients treated with primary ADT. Materials and Methods: 80 Patients who underwent primary ADT for newly diagnosed PC at 3 university hospitals were randomly assigned to CAB group (Group 1, N=40) and LHRH agonist alone group (Group 2, N=40) from April 2014 to June 2018. Patients who were treated with prior ADT, neoadjuvant or salvage ADT were excluded. Leuprolide (Luphere depot 3.75mg) and antiandrogen (bicalutamide 50mg) were used to minimize confounding effect due to medication. Patients’ QOL was evaluated at baseline, post-ADT 3 mo and 6 mo using validated EORTC QLQ-C30, PR25 and depression questionnaire (PHQ-9). Difference of >10 points in the EORTC domain scores was defined as “clinically significant”. Results: In baseline clinicopathological characteristics and QOL, there was no significant difference between the two groups in both ITT and PP set. QOL following ADT are summarized in Table 1. At 3 mo after ADT, Group 1 had significantly lower pain scores than Group 2 (mean ± SD, ITT set: 4.76±9.54 vs. 16.18±19.46, p=0.003, PP set: 5.05±9.76 vs. 16.67±19.72, p=0.004), while Group 1 had poorer diarrhea symptom than Group 2 without clinical significance (PP set: 9.09±17.23 vs. 2.15±8.32, p=0.047). No significant differences were observed in the other C30, PR25 domains and PHQ-9 at 3 months and 6 months. Conclusion: There was no significant difference in patient QOL according to the ADT method, except that CAB results in significantly better pain relief than LHRH agonist alone at 3 months following ADT. Our results will provide useful information regarding QOL of PC patients undergoing ADT. keywords : prostate cancer, androgen deprivation therapy, quality of life